Key Takeaways:
- Telepsychiatry and interventional psychiatry are both expanding rapidly, but existing virtual care workflows are not yet designed to integrate advanced treatment pathways.
- Current telepsychiatry platforms create a care gap by failing to identify, coordinate, and retain patients who could benefit from interventional treatments like TMS or esketamine.
- Redesigning workflows with structured data, EHR integration, and pre-procedure education can enable telepsychiatry to serve as a true entry point into interventional care.
- Hybrid care models with remote clinician participation and continuous outcome tracking can improve access, scalability, and treatment effectiveness when supported by the right infrastructure.
Telepsychiatry has come a long way in a short time. What began as a pandemic-era workaround has matured into a legitimate and widely adopted model for delivering psychiatric evaluations, medication management, and therapy. For millions of patients, virtual mental health care has been genuinely transformative.
Likewise, interventional psychiatry is moving from the margins to the mainstream. Transcranial magnetic stimulation (TMS), esketamine nasal spray, ketamine infusions, and electroconvulsive therapy (ECT) are no longer options reserved for the most treatment-resistant cases. They are increasingly recognized as evidence-based tools that should be considered earlier in the treatment continuum for a significant subset of patients.
It is worth being clear, though, that interventional psychiatry is not a monolith. Some components are a natural fit for telemedicine. Others are not. Understanding that distinction is the starting point for any serious conversation about workflow redesign. As that shift accelerates, telepsychiatry platforms and the workflows built around them face a design challenge they were not originally built to solve.
The workflow gap
The core limitation is structural. Current telepsychiatry platforms are optimized for a relatively linear clinical workflow: Patient schedules, the clinician evaluates, a prescription is written, and a follow-up is booked. That model works well for medication management and ongoing therapy. It is not currently ideal for coordinating care across a distributed team that includes remote clinicians, in-person technicians, and multiple treatment modalities.
The result is a gap. Patients who might benefit from TMS or esketamine are either not being identified through virtual care channels or are being referred out with little continuity and handed off to an interventional provider with minimal context and no structured follow-up pathway back into their telepsychiatry relationship. Closing that gap requires rethinking the telepsychiatry workflow from the ground up, not simply adding a referral button.
What redesigned workflows could look like
The first priority in a redesigned approach is structured candidate identification. Telepsychiatry platforms should support standardized data collection across every evaluation, including structured tracking of prior treatment trials, medication response history, functional impairment scores, and patient-reported outcomes over time. This longitudinal data is precisely what clinicians need to identify patients who have not responded adequately to first- and second-line treatments and who may be appropriate candidates for interventional care.
Electronic health record integration is critical here. When telepsychiatry platforms operate in silos and are disconnected from the EHR systems used by interventional providers, then continuity breaks down. A patient’s virtual psychiatrist and their TMS technician may have no real-time visibility into each other’s clinical notes, treatment parameters, or observed responses. Building interoperability between telepsychiatry platforms and the clinical systems used in interventional settings is a prerequisite for safe, coordinated care.
The second priority is pre-procedure patient preparation. Interventional treatments carry a higher burden of patient education than a standard medication prescription. TMS involves multiple sessions per week over several weeks. Ketamine has dissociative effects that require specific informed consent and monitoring protocols. ECT remains stigmatized and widely misunderstood. A patient encountering these options without prior preparation in the middle of an interventional evaluation is not set up for success.
Telepsychiatry is ideally positioned to do this work. Dedicated pre-procedure video visits, structured psychoeducation tools embedded in the platform, and asynchronous content delivery can significantly improve patient readiness before an in-person interventional appointment. This is not a clinical luxury. It is a workflow design decision that affects treatment adherence and outcomes.
Remote participation in the treatment process
One area where the hybrid model holds particular promise is clinician participation in treatment sessions themselves. Consider motor threshold determination in TMS, which is the calibration process that identifies the precise stimulation strength needed to penetrate a patient’s skull and reach the cortex. A technician places the coil over the area of the brain controlling hand movement, starts at a low intensity, and gradually increases until a visible hand twitch confirms cortical penetration. Go too far or not far enough, and the twitch doesn’t appear. It is a precise, clinically meaningful process, and it can be conducted entirely with a remote clinician guiding a trained on-site technician via video in real time. The patient sees the clinician on a screen. The technician is the clinician’s eyes and hands. The clinical judgment driving the process is happening remotely.
This model has practical implications for workforce distribution. A psychiatrist with specialized expertise in interventional care does not need to be physically co-located with every treatment site they oversee. Remote participation protocols, clearly defined technician scopes of practice, and reliable video infrastructure could allow a single expert clinician to support multiple sites and extend access without requiring proportional increases in specialized staffing.
Emerging psychedelic-assisted therapies are likely to follow a similar model. Protocols for psilocybin and MDMA-assisted treatment require on-site nursing staff and therapists for safety, but the prescribing physician’s role may be accomplished through a structured video visit at the outset of each session. Reviewing the plan, completing informed consent, and remaining available for consultation while on-site staff manage administration can all be facilitated remotely. The technology framework to support this exists. The workflow protocols to govern it are still being developed.
Follow-up as a data infrastructure problem
Post-treatment follow-up is an area where the current model potentially falls short. Response to interventional treatments, particularly TMS, can vary significantly across patients and across time. A patient who responds well to an initial course may experience symptom recurrence months later and benefit from maintenance treatment. Capturing that signal requires consistent, structured symptom tracking between sessions.
Wearables, app-based mood-monitoring tools, and validated digital assessments integrated into the telepsychiatry platform can generate a continuous stream of outcome data that informs clinical decision-making in ways that periodic appointments cannot. The challenge is less about what technology can do and more about whether health IT systems are designed to aggregate, surface, and act on that data in a clinically meaningful way.
Getting the infrastructure right
There is an important caution embedded in this opportunity. The risk in any period of rapid platform development is that technology capabilities begin to drive clinical protocol design rather than the other way around. Building a workflow because the technology makes it possible, rather than because the evidence supports it, places risk on patients in ways that are neither ethical nor sustainable. Health IT professionals designing the next generation of telepsychiatry infrastructure should hold that principle close.
The design decisions being made now about interoperability, structured data collection, remote participation protocols, and follow-up monitoring will determine whether telepsychiatry becomes a genuine gateway to precision psychiatric care or remains a parallel track that rarely intersects with it. That is a technology and workflow challenge as much as it is a clinical one. Getting it right means letting the evidence lead and building platforms that are designed to serve patients, not to serve the paradigm.
About Mottsin Thomas, MD
Mottsin Thomas, MD, is a board-certified psychiatrist and the founder of bonmente, a California-based comprehensive telepsychiatry practice. Committed to clinical excellence, Dr. Thomas rigorously evaluates emerging innovations in psychiatry to ensure that new therapies and technologies provide patients meaningful, measurable improvements in outcomes.
